SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Dwyer who wrote (205)12/11/1997 8:40:00 PM
From: r. peter Dale  Read Replies (1) of 4474
 
John - The article is interesting and the claims are valid to the degree they support the efficacy of the delivery system. The overall success of the 'principle' suggests Ariad's approach can work in vivo.

My problem with the study is that is a flawed/incomplete design: there is only one vector delivery time point presented - three weeks prior to striatal 6-OHDA injection (e.g. the Parkinson-like lesion). In a more 'lifelike' scenario - where the lesion already exists or is progressing - the results may be dramatically different. Having high levels of growth factor present prior to 'disease' onset is of questionable value.

A 'who cares?' to this criticism would not be inappropriate. I'll discount any Parkinson's relevance and read this as a significant methodology paper.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News